The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

An investigational multitarget stool DNA test for screening colorectal cancer detects significantly more cancers than the currently available fecal immunochemical test (FIT), researchers report. But ...

Colorectal cancer incidence and mortality have increased among younger adults in recent years, with the most significant increase seen in those ages 40 to 49. Starting FIT screening early was tied to ...

Close to 50,000 Americans will die from colorectal cancer (CRC) in 2016, making it the second-leading cause of cancer-related death in this country (behind only lung cancer).1 What makes the statistic ...

Please provide your email address to receive an email when new articles are posted on . People in rural areas experience a variety of barriers to CRC screening. A mailed fecal immunochemical test ...

Chaoyuan Kuang, MD, PhD, Co-Leader, GI Clinical and Translational Research, at Montefiore Einstein Comprehensive Cancer Center, and Othon Wiltz, MD, Colon and Rectal Surgeon, for Montefiore Einstein ...

The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer, NBC News reported. The test isn't meant to replace colonoscopies, but is ...

A retrospective study of data from patients aged 50 to 75 years in the Kaiser Permanente Northern California health system showed detection of colorectal cancer by colonoscopy fell by 4% in 2020 vs ...

Colon cancer is the second-deadliest cancer in the US, partly due to low screening rates. New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.

The Cologuard Plus test is more accurate than the original Cologuard, and should be easier to mail in for stool analysis. The newest version of Cologuard, an at-home colon cancer screening test, ...

COPENHAGEN, Denmark--(BUSINESS WIRE)--COLOTECT™ 3.0 is a non-invasive colorectal cancer screening test developed by BGI, and will be launched in early 2023. BGI plans to release pre-clinical ...